Literature DB >> 11689768

The gelatin-derived plasma substitute Gelofusine causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption.

M A ten Dam1, A J Branten, I S Klasen, J F Wetzels.   

Abstract

PURPOSE: Proteinuria is frequently encountered in patients in the intensive care unit, most likely as a result of renal tubular cell injury. It has been reported that gelatin-derived plasma substitutes contribute to an increase in renal protein excretion. The aim of this study was to investigate the magnitude and the mechanism of the proteinuric effect of Gelofusine, a modified gelatin.
MATERIALS AND METHODS: In six healthy male subjects, renal hemodynamics and urinary protein excretion were measured before and after infusion of 330 mL of Gelofusine.
RESULTS: Gelofusine had a minor effect on blood pressure, glomerular filtration rate, effective renal plasma flow, and on urinary excretion of immunoglobulin, and albumin. In contrast, there was a major increase in the urinary excretion of the low-molecular-weight proteins beta2-microglobulin (from 0.06 +/- 0.04 to 43.52 +/- 11.75 microg/min; P <.01) and alpha1-microglobulin (from 11 +/- 8 to 72 +/- 24 microg/min; P <.01). The urinary excretion of N-acetyl-beta-D-glucosaminidase (beta-NAG) remained unchanged, suggesting that there was no significant renal tubular cell injury.
CONCLUSIONS: When analyzing proteinuria in patients in the intensive care unit it should be considered that Gelofusine increases the urinary excretion of proteins, in particular those of low molecular weight. This effect is most likely due to competitive inhibition of tubular protein reabsorption. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689768     DOI: 10.1053/jcrc.2001.28787

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  11 in total

1.  Renal impairment in cardiac surgery patients receiving hydroxyethyl starch.

Authors:  Christian J Wiedermann
Journal:  Intensive Care Med       Date:  2004-01-16       Impact factor: 17.440

Review 2.  In neonates requiring intravascular volume resuscitation is the use of gelofusine safe and efficacious?

Authors:  Minesh Khashu; Velur Balasubramaniam
Journal:  Arch Dis Child       Date:  2007-11       Impact factor: 3.791

3.  Gelofusine Ameliorates Colistin-Induced Nephrotoxicity.

Authors:  Sivashangarie S Sivanesan; Mohammad A K Azad; Elena K Schneider; Maizbha U Ahmed; Jiayuan Huang; Jiping Wang; Jian Li; Roger L Nation; Tony Velkov
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

Review 4.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Authors:  Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-14       Impact factor: 9.236

5.  Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice.

Authors:  Erik Vegt; Marleen Melis; Annemarie Eek; Monique de Visser; Maarten Brom; Wim J G Oyen; Martin Gotthardt; Marion de Jong; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-18       Impact factor: 9.236

6.  Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction.

Authors:  Karin G F Gerritsen; Jan Willem Leeuwis; Maarten P Koeners; Stephan J L Bakker; Willem van Oeveren; Jan Aten; Lise Tarnow; Peter Rossing; Jack F M Wetzels; Jaap A Joles; Robbert Jan Kok; Roel Goldschmeding; Tri Q Nguyen
Journal:  J Diabetes Res       Date:  2015-06-15       Impact factor: 4.011

7.  Gelofusine Attenuates Tubulointerstitial Injury Induced by cRGD-Conjugated siRNA by Regulating the TLR3 Signaling Pathway.

Authors:  Bohong Cen; Wenjie Liao; Zhen Wang; Linyuan Gao; Yuanyi Wei; Wen Huang; Shuai He; Wei Wang; Xiaoxia Liu; Xinghua Pan; Aimin Ji
Journal:  Mol Ther Nucleic Acids       Date:  2018-03-14       Impact factor: 8.886

8.  Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.

Authors:  Marleen Melis; Magda Bijster; Monique de Visser; Mark W Konijnenberg; Jan de Swart; Edgar J Rolleman; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

9.  Protective effect of Gelofusine against cRGD-siRNA-induced nephrotoxicity in mice.

Authors:  Wenjie Liao; Yixin Qin; Lumin Liao; Bohong Cen; Zhuomin Wu; Yuanyi Wei; Zhen Wang; Guoxian Li; Aimin Ji
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

10.  Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.

Authors:  Anzhelika Vorobyeva; Maryam Oroujeni; Sarah Lindbo; Sophia Hober; Tianqi Xu; Yongsheng Liu; Sara S Rinne; Javad Garousi
Journal:  Molecules       Date:  2020-09-28       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.